Literature DB >> 23552131

Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain.

Luis Almenar1, Beatriz Díaz, Aurelio Quesada, Carlos Crespo, Belén Martí, Stuart Mealing, Cecilia Linde, Claude Daubert.   

Abstract

OBJECTIVES: The aim of the study was to combine clinical results from the European Cohort of the REVERSE study and costs associated with the addition of cardiac resynchronization therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic (NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac dyssynchrony in Spain.
METHODS: A Markov model was developed with CRT + OMT (CRT-ON) versus OMT only (CRT-OFF) based on a retrospective cost-effectiveness analysis. Raw data was derived from literature and expert opinion, reflecting clinical and economic consequences of patient's management in Spain. Time horizon was 10 years. Both costs (euro 2010) and effects were discounted at 3 percent per annum.
RESULTS: CRT-ON showed higher total costs than CRT-OFF; however, CRT reduced the length of hospitalization in ICU by 94 percent (0.006 versus 0.091 days) and general ward in by 34 percent (0.705 versus 1.076 days). Surviving CRT-ON patients (88.2 percent versus 77.5 percent) remained in better functional class longer, and they achieved an improvement of 0.9 life years (LYGs) and 0.77 years quality-adjusted life years (QALYs). CRT-ON proved to be cost-effective after 6 years, except for the 7th year due to battery depletion. At 10 years, the results were €18,431 per LYG and €21,500 per QALY gained. Probabilistic sensitivity analysis showed CRT-ON was cost-effective in 75.4 percent of the cases at 10 years.
CONCLUSIONS: The use of CRT added to OMT represents an efficient use of resources in patients suffering from heart failure in NYHA functional classes I and II.

Entities:  

Mesh:

Year:  2013        PMID: 23552131     DOI: 10.1017/S0266462313000123

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  4 in total

Review 1.  Cardiac resynchronization therapy in patients with mild heart failure is a reversal therapy.

Authors:  Sadeq Ali-Hassan-Al-Saegh; Seyed Jalil Mirhosseini; Ali Akbar Karimi-Bondarabadi; Azadeh Sahidzadeh; Parisa Mahdavi; Mahbube Tahernejad; Safieyehsadat Heydari; Alexander Weymann; Mohamed Zeriouh; Anton Sabashnikov; Aron-Frederik Popov
Journal:  Indian Heart J       Date:  2016-08-25

2.  Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario.

Authors:  Louise Perrault; Sybil Dahan; Ange Christelle Iliza; Jacques LeLorier; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2017-02-20       Impact factor: 2.471

3.  Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure.

Authors:  Lan Gao; Marj Moodie
Journal:  BMJ Open       Date:  2019-09-05       Impact factor: 2.692

4.  Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.

Authors:  Phil McEwan; Oliver Darlington; John J V McMurray; Pardeep S Jhund; Kieran F Docherty; Michael Böhm; Mark C Petrie; Klas Bergenheim; Lei Qin
Journal:  Eur J Heart Fail       Date:  2020-09-15       Impact factor: 15.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.